Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)

Chi­na ap­proves BC­MA CAR-T ther­a­py for mul­ti­ple myelo­ma, with In­novent beat­ing Leg­end in race to be first

In­novent and IA­SO Bio re­ceived the first ap­proval in Chi­na for a CAR-T ther­a­py for mul­ti­ple myelo­ma.

The ther­a­py, known as eque­cab­ta­gene au­toleu­cel, will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.